Sort by

Send to

Choose Destination

Search results

Items: 5


The STAT3 Inhibitor Galiellalactone Reduces IL6-Mediated AR Activity in Benign and Malignant Prostate Models.

Handle F, Puhr M, Schaefer G, Lorito N, Hoefer J, Gruber M, Guggenberger F, Santer FR, Marques RB, van Weerden WM, Claessens F, Erb HHH, Culig Z.

Mol Cancer Ther. 2018 Dec;17(12):2722-2731. doi: 10.1158/1535-7163.MCT-18-0508. Epub 2018 Sep 25.


Fractionated Radiation of Primary Prostate Basal Cells Results in Downplay of Interferon Stem Cell and Cell Cycle Checkpoint Signatures.

Guggenberger F, van de Werken HJG, Erb HHH, Cappellano G, Trattnig K, Handle F, Peer S, Schäfer G, Jenster G, Culig Z, Skvortsova I, Santer FR.

Eur Urol. 2018 Dec;74(6):847-849. doi: 10.1016/j.eururo.2018.06.002. Epub 2018 Jun 18. No abstract available.


Olaparib is effective in combination with, and as maintenance therapy after, first-line endocrine therapy in prostate cancer cells.

Feiersinger GE, Trattnig K, Leitner PD, Guggenberger F, Oberhuber A, Peer S, Hermann M, Skvortsova I, Vrbkova J, Bouchal J, Culig Z, Santer FR.

Mol Oncol. 2018 Apr;12(4):561-576. doi: 10.1002/1878-0261.12185. Epub 2018 Mar 15.


Interleukin-4 induces a CD44high /CD49bhigh PC3 subpopulation with tumor-initiating characteristics.

Erb HHH, Guggenberger F, Santer FR, Culig Z.

J Cell Biochem. 2018 May;119(5):4103-4112. doi: 10.1002/jcb.26607. Epub 2018 Jan 19.


Attenuation of nucleoside and anti-cancer nucleoside analog drug uptake in prostate cancer cells by Cimicifuga racemosa extract BNO-1055.

Dueregger A, Guggenberger F, Barthelmes J, Stecher G, Schuh M, Intelmann D, Abel G, Haunschild J, Klocker H, Ramoner R, Sampson N.

Phytomedicine. 2013 Nov 15;20(14):1306-14. doi: 10.1016/j.phymed.2013.07.009. Epub 2013 Aug 23.


Supplemental Content

Loading ...
Support Center